Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
企業コードAXGN
会社名AxoGen Inc
上場日Dec 17, 1986
最高経営責任者「CEO」Mr. Michael Donald (Mike) Dale
従業員数451
証券種類Ordinary Share
決算期末Dec 17
本社所在地13631 Progress Blvd.
都市ALACHUA
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号32615
電話番号13864626817
ウェブサイトhttps://www.axogeninc.com/
企業コードAXGN
上場日Dec 17, 1986
最高経営責任者「CEO」Mr. Michael Donald (Mike) Dale
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし